RxDoctor Payments Data

Richard Gralla

Hematology & Oncology · New Hyde Park, NYNPI 1710167002

Payments from drug & device makers

$322,668in general payments, 2019–2025

Across 101 payments — averaging $3194.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$163K
  • Helsinn Healthcare SA$100K
  • Purdue Pharma$22K
  • Vifor (international) Ltd.$17K
  • Eli Lilly$12K
  • Bayer$6K
  • plus $3K from 2 others

What the payments were for

  • Consulting fees$70,33844%
  • Speaking & faculty fees$29,32218%
  • Travel & lodging$58,22337%
  • Food & beverage$1,3031%
  • Education$430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck25$163,439
Helsinn Healthcare SA36$100,398
Purdue Pharma1$21,640
Vifor (international) Ltd.3$16,501
Eli Lilly30$11,766
Bayer2$6,073
Heron Therapeutics, Inc.2$2,123
AstraZeneca2$728

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$322,668 in reported general payments places this provider in the 80th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
Erlotinib Hcl11$53,709

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →